Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 39,800 shares, a growth of 26.3% from the December 31st total of 31,500 shares. Based on an average trading volume of 569,300 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Price Performance

ALPMY stock opened at $9.68 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.86 and a debt-to-equity ratio of 0.41. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The stock has a market cap of $17.52 billion, a PE ratio of 46.10 and a beta of 0.34. The company has a 50-day moving average price of $9.87 and a 200 day moving average price of $10.97.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. The firm had revenue of $3.11 billion for the quarter. Equities research analysts anticipate that Astellas Pharma will post 0.58 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.